{
    "id": "26920239",
    "text": "Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008. == Synthesis == 450px == See also == * Protein kinase inhibitor == References == Category:Tyrosine kinase inhibitors Category:Oxazoles Category:Triazoles Category:Trifluoromethyl compounds ",
    "title": "Mubritinib"
}